Your email has been successfully added to our mailing list.

×
0 0 -0.000371747211895969 -0.000371747211895969 0.00371747211895903 0.00371747211895903 0.0048327137546468 0.0130111524163568
Stock impact report

Final Results of Albireo’s Phase 2 Study of A4250 in Children with Cholestatic Liver Disease Presented at The Liver Meeting® 2017

Albireo Pharma, Inc. (ALBO) 
Last albireo pharma, inc. earnings: 3/2 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.albireopharma.com/investor-relations
Company Research Source: GlobeNewswire
— A4250 reduced serum bile acids and improved pruritus in most patients, exhibited a favorable overall tolerability profile — — Albireo to conduct Phase 3 study in children with progressive familial intrahepatic cholestasis — BOSTON, Oct. 20, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that final results from its Phase 2 study of lead product candidate A4250 in children with cholestatic liver disease will be presented at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2017 in Washington, D.C. A poster presentation of the study will be made by Ekkehard Sturm, M.D., Ph.D., an investigator for the study, on October 21, followed by an ePoster presentation chosen by the leaders of the AASLD Special Interest Groups on October 22. In the study, A4250 reduced serum bile acids (sBA) and improved pruritus in most pa Show less Read more
Impact Snapshot
Event Time:
ALBO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ALBO alerts
Opt-in for
ALBO alerts

from News Quantified
Opt-in for
ALBO alerts

from News Quantified